文献速递免疫规划

碳水化合物脂肪酸单硫酸酯是安全有效的体液免疫佐剂

Carbohydrate fatty acid monosulphate esters are safe and effective adjuvants for humoral responses.
PubMed 文献 · Vaccine · 2017-05-04

研究在兔和雪貂中评估了角鲨烷水包油乳剂配方的合成碳水化合物脂肪酸单硫酸酯(CMS)佐剂。CMS不引起体温升高或局部反应,抗体滴度较明矾或AddaVax佐剂显著更高,且不激活人TLR4,作者认为其是弱免疫原和单剂疫苗的有前景候选佐剂。

要点

  • 兔肌内注射CFASE后体温升高1°C,次日恢复正常,效应随剂量增加但不随注射次数(最多5次)增加。
  • CMS佐剂在兔中不引起体温升高或局部反应,抗体滴度较明矾首次免疫后高约30倍、二次免疫后高>100倍。
  • 雪貂中CMS佐剂HAI抗体滴度较AddaVax高10-20倍,单次免疫即可达到或超过两次免疫的基准佐剂效果。

核心结论

  • 作者认为合成CMS佐剂是弱免疫原和单剂疫苗的有前景候选佐剂。
  • 作者认为体温升高、局部反应或TLR4激活并非高佐剂活性的先决条件。

研究设计与样本

  • 研究在兔和雪貂中评估角鲨烷水包油乳剂配方的合成碳水化合物脂肪酸单硫酸酯(CMS)佐剂。
  • 兔模型中比较CFASE与CMS佐剂,抗原为纯化重组疟疾嵌合抗原R0.10C。
  • 雪貂模型中比较CMS佐剂与MF59样AddaVax佐剂,抗原为7.5μg灭活甲型流感病毒A/H7N9。

主要发现

  • 兔肌内注射CFASE后体温升高1°C,次日恢复正常,效应随CFASE剂量增加但不随注射次数(最多5次)增加。
  • 加强免疫后抗原增强体温升高(P<0.01),初次免疫后无此效应。
  • 兔中CMS佐剂不引起体温升高或局部反应,抗体滴度较明矾首次免疫后高约30倍、二次免疫后高>100倍。
  • 雪貂中CMS佐剂HAI抗体滴度首次免疫后增加100倍、二次免疫后增加25倍,较AddaVax高10-20倍。
  • 两种模型中单次CMS佐剂免疫的滴度与两次基准佐剂免疫相似或更高,未检测到全身和局部不良反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Carbohydrate fatty acid sulphate esters (CFASEs) formulated in a squalane-in-water emulsion are effective adjuvants for humoral responses to a wide range of antigens in various animal species but rise in body temperature and local reactions albeit mild or minimal hampers application in humans. In rabbits, body temperature increased 1°C one day after intramuscular (IM) injection, which returned to normal during the next day. The effect increased with increasing dose of CFASE but not with the number of injections (up to 5). Antigen enhanced the rise in body temperature after booster immunization (P<0.01) but not after priming. Synthetic CFASEs are mixtures of derivatives containing no sulphate, one or multiple sulphate groups and the monosulphate derivatives (CMS) were isolated, incorporated in a squalane in-water emulsion and investigated. In contrast to CFASE, CMS adjuvant did not generate rise in body temperature or local reactions in rabbits immunized with a purified, recombinant malaria chimeric antigen R0.10C. In comparison to alum, CMS adjuvant revealed approximately 30-fold higher antibody titres after the first and >100-fold after the second immunization. In ferrets immunized with 7.5μg of inactivated influenza virus A/H7N9, CMS adjuvant gave 100-fold increase in HAI antibody titres after the first and 25-fold after the second immunisation, which were 10-20-fold higher than with the MF59-like AddaVax adjuvant. In both models, a single immunisation with CMS adjuvant revealed similar or higher titres than two immunisations with either benchmark, without detectable systemic and local adverse effects. Despite striking chemical similarities with monophospholipid A (MPL), CMS adjuvant did not activate human TLR4 expressed on HEK cells. We concluded that the synthetic CMS adjuvant is a promising candidate for poor immunogens and single-shot vaccines and that rise in body temperature, local reactions or activation of TLR4 is not a pre-requisite for high adjuvanticity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hilgers LAT, Platenburg PPLI, Bajramovic J, et al. Carbohydrate fatty acid monosulphate esters are safe and effective adjuvants for humoral responses. Vaccine. 2017. PMID: 28479181. doi:10.1016/j.vaccine.2017.04.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。